Enanta Pharmaceuticals reported U$480 million in Equity Capital and Reserves for its second fiscal quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
Abbvie U$ 14708M 22123M
Acorda Therapeutics U$ 290M 16M
Amgen U$ 10659M 1174M
Anika Therapeutics U$ 288.444M 5.25M
AstraZeneca 12237M 1459M
Biocryst Pharmaceuticals U$ 76M 73M
Biogen U$ 10758.5M 550.2M
Bristol Myers Squibb U$ 49094M 817M
Clovis Oncology U$ -98M 29M
Enanta Pharmaceuticals U$ 480M 5M
Gilead Sciences U$ 18027M 4040M
GlaxoSmithKline 13593M 499M
Halozyme Therapeutics U$ 105.577M 47.535M
Insmed 40531800 19861700
Intercept Pharmaceuticals U$ -78.796M 44.077M
Ligand Pharmaceuticals U$ 695.003M 33.107M
Merk U$ 27642M 1437M
Neurocrine Biosciences U$ 831M 131M
Novavax U$ 384M 408M
Pfizer U$ 64336M 690M
Ptc Therapeutics U$ 572.494M 43.76M
Sarepta Therapeutics U$ 1042M 102M
Vertex Pharmaceuticals U$ 7519.242M 1057.588M
YTE U$ 2344.604M 406.883M